Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
The study assessed the anti-PD-1 monoclonal antibody pembrolizumab in patients with advanced tumors. Objective responses were observed in 30 (29%) of...
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
The study compared pembrolizumab plus axitinib and sunitinIB for advanced renal cell carcinoma. Median follow-up of 30.6 months showed continued clini...
Recent Posts
-
-
What Causes Sciatica | Dr. Kalyan Bommakanti
11 May 2022 -
